Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Miptenalimab by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval
Miptenalimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...
Data Insights
Miptenalimab by Boehringer Ingelheim International for Hepatocellular Carcinoma: Likelihood of Approval
Miptenalimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...